Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index; 35 of the 231 sources its claims cite were checked for support.

Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document

Open access

Abstract

Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Methods: The American Thyroid Association (ATA), British Thyroid Association (BTA), and European Thyroid Association (ETA) held a joint conference on November 3, 2019 (live-streamed between Chicago and London) to review new basic science and clinical evidence regarding combination therapy with presentations and input from 12 content experts. After the presentations, the material was synthesized and used to develop Summary Statements of the current state of knowledge. After review and revision of the material and Summary Statements, there was agreement that there was equipoise for a new clinical trial of combination therapy. Consensus Statements encapsulating the implications of the material discussed with respect to the design of future clinical trials of LT4/LT3 combination therapy were generated. Authors voted upon the Consensus Statements. Iterative changes were made in several rounds of voting and after comments from ATA/BTA/ETA members. Results: Of 34 Consensus Statements available for voting, 28 received at least 75% agreement, with 13 receiving 100% agreement. Those with 100% agreement included studies being powered to study the effect of deiodinase and thyroid hormone transporter polymorphisms on study outcomes, inclusion of patients dissatisfied with their current therapy and requiring at least 1.2 µg/kg of LT4 daily, use of twice daily LT3 or preferably a slow-release preparation if available, use of patient-reported outcomes as a primary outcome (measured by a tool with both relevant content validity and responsiveness) and patient preference as a secondary outcome, and utilization of a randomized placebo-controlled adequately powered double-blinded parallel design. The remaining statements are presented as potential additional considerations. Discussion: This article summarizes the areas discussed and presents Consensus Statements to guide development of future clinical trials of LT4/LT3 combination therapy. The results of such redesigned trials are expected to be of benefit to patients and of value to inform future thyroid hormone replacement clinical practice guidelines treatment recommendations.

Overview

CoChat Summary

## TL;DR

This consensus document does not report a new clinical trial; it synthesizes prior basic, translational, and clinical evidence to guide future LT4/LT3 combination-therapy trials in hypothyroidism. The authors conclude that prior trials were heterogeneous and often underoptimized, and they recommend better patient selection, thyroid-specific patient-reported outcomes, and more physiological dosing/monitoring strategies.

## Key findings

  • The paper states that 14 clinical trials of LT4/LT3 combination therapy had not shown a consistent benefit.
  • Of 34 Consensus Statements available for voting, 28 achieved agreement from at least 75% of the group, and 13 reached 100% consensus.
  • The paper reports that among prior combination-therapy trials, 2 trials contributing 92 participants showed superiority of combination therapy on multiple QoL/mood measures, 2 trials contributing 633 participants showed superiority on a minority of measures, and the remaining 9 trials showed no benefit.
  • For neurocognitive outcomes, 1 trial of 33 patients showed benefit on multiple measures, 1 trial of 26 participants showed benefit on a minority of measures, and 8 trials showed no benefit; the paper also notes prior trial ratios ranged from 4:1 to 19:1 T4:T3, and LT3/T3 pharmacologic equivalence was estimated at about 1:3.

## Methods

  • Consensus document based on a joint ATA/BTA/ETA symposium held on November 3, 2019, with presentations and input from 12 content experts, followed by workshops, synthesis of material into summary statements, and iterative voting/revision.
  • The source material was organized into 11 topics; 34 Consensus Statements were drafted and voted on by the authors.
  • The paper is a narrative consensus/review, drawing on prior clinical trials, mechanistic studies, and modeling rather than reporting original participant-level trial data.

## Limitations

  • The paper itself states that prior studies had small sample sizes, short duration, multiple comparisons, once-daily LT3 dosing, and heterogeneous dosing/outcome measures, which made results hard to compare or meta-analyze.
  • It also states that patient preference was not validated with adequate PRO measures in earlier trials, and that many trials did not specifically recruit patients dissatisfied with LT4 or with persistent symptoms.
  • Evident from the text: this is a consensus/review document, so its recommendations are not direct evidence from a new randomized trial; they depend on the quality and heterogeneity of the cited literature.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1159/000512970

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

25 Valid · 14 Not valid · 124 Not checked · 70 Own results and interpretations

118 more claims · 8 with their cited sources checked

Create a free account to see all 233 claims and to verify the 196 references still open.

See all claims — free account
  • It may state two separate claims as one. 69
  • Probably not a substantial claim. 60

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 114 references

Research works printed but not linked: 6

  1. Jo, 2019, Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain, J Clin Invest, 129, 230, 10.1172/jci123176 · DOI · Paper page
  2. Escobar-Morreale, 2005, Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone, Ann Intern Med, 142, 412, 10.7326/0003-4819-142-6-200503150-00007 · DOI · Paper page
  3. Jonklaas, 2008, Triiodothyronine levels in athyreotic individuals during levothyroxine therapy, JAMA, 299, 769, 10.1001/jama.299.7.769 · DOI · Paper page
  4. Watt T (CaplanM, editor). Book Chapter: Measuring impact of benign thyroid diseases on quality of life. Reference Module in Biomedical Sciences. Elsevier; 2018.ISBN: 978-0-12-801238-3.
  5. O’Boyle CA , HickeyA, JoyceCR, O’MalleyK, HiltbrunnerB. Evaluation of Individual Quality of Life (SEIQoL). Administration manual. Dublin: Royal College of Surgeons in Ireland; 1993. pp. 1–73. In: https://repository.rcsi.com/articles/The_Schedule_for_the_Evaluation_of_Individual_Quality_of_Life_SEIQoL_Administration_Manual_/10770242, ed.
  6. Siegmund, 2004, Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism, Clin Endocrinol (Oxf), 60, 750, 10.1111/j.1365-2265.2004.02050.x · DOI · Paper page

Cited by

See all 81

Metadata

Authors
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., Watt, T., & Dayan, C. M.
Affiliations
  • Georgetown University (US)
  • University of Chicago (US)
  • University of Pennsylvania (US)
  • Virginia Commonwealth University (US)
  • Amsterdam University Medical Centers (NL)
  • University of Duisburg-Essen (DE)
  • Rush University (US)
  • Herlev Hospital (DK)
  • University Health Network (CA)
  • Copenhagen University Hospital (DK)
  • Cardiff University (GB)
Venue
European Thyroid Journal
Published
2021-02-16
Volume
10
Issue
1
Pages
10-38
ISSN
  • 2235-0640 (ISSN-L)
  • 2235-0802
OpenAlex
W3133140094
Cited by
78
References
114
Citations by year
2026: 8 · 2025: 13 · 2024: 15 · 2023: 11 · 2022: 22 · 2021: 9
FWCI
10.64
Type
journal article
Language
en
Open access
Locations
  • European Thyroid Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
National Institute on Aging (K24AG042765)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
levothyroxine, liothyronine, combination thyroid hormone therapy, hypothyroidism, thyroid hormone replacement, clinical trial design, patient-reported outcomes, patient preferences, trial power

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. https://app.cochat.ai/papers/10.1159/000512970
The paper
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., Watt, T., & Dayan, C. M. (2021). Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. European Thyroid Journal. https://doi.org/10.1159/000512970

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.